These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 6371017)

  • 41. Investigational therapies for epithelial ovarian cancer.
    Kavanagh JJ
    Clin Obstet Gynecol; 1985 Dec; 28(4):846-52. PubMed ID: 4075634
    [No Abstract]   [Full Text] [Related]  

  • 42. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intraperitoneal chemotherapy versus no treatment in patients with ovarian carcinoma who are in complete clinical remission.
    Menczer J; Ben-Baruch G; Rizel S; Brenner H
    Cancer; 1992 Oct; 70(7):1956-9. PubMed ID: 1525772
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma.
    Leonard RC; Smart GE; Livingstone JR; Cornbleet MA; Kerr GR; Fletcher S; Webb JN; Smyth JF
    Cancer Chemother Pharmacol; 1989; 23(2):105-10. PubMed ID: 2491962
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cisplatin and cyclophosphamide in advanced ovarian carcinoma: activity and toxicity of an ambulatory regimen.
    Zambetti M; Gianni L; Di Re F; Spatti G; Fontanelli R; Escobedo A; De Palo G; Bonadonna G
    Am J Clin Oncol; 1990 Jun; 13(3):199-203. PubMed ID: 2161174
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of surgical debulking on the response of patients with ovarian carcinoma to chemotherapy.
    McDermott DF; Jaffe EA; Coleman M; Pasmantier MW
    Am J Clin Oncol; 1988 Oct; 11(5):520-3. PubMed ID: 3177252
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Primary chemotherapy in epithelial ovarian cancer.
    Hurwitz HI; McGuire WP
    Obstet Gynecol Clin North Am; 1994 Mar; 21(1):141-54. PubMed ID: 7912423
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.
    Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Vriesendorp R; Kooyman CD; van Lindert AC; Hamerlynck JV; van Lent M; van Houwelingen JC
    Lancet; 1984 Sep; 2(8403):594-600. PubMed ID: 6147640
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy.
    Eoh KJ; Lee JY; Nam EJ; Kim S; Kim YT; Kim SW
    J Korean Med Sci; 2017 Dec; 32(12):2021-2028. PubMed ID: 29115086
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recent advances in the management of women with ovarian cancer.
    Eltabbakh GH
    Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Chemotherapy of advanced ovarian cancer. Göttingen-Hannover studies].
    Kühnle H; Hilfrich J
    Onkologie; 1985 Dec; 8(6):374-82. PubMed ID: 3912694
    [TBL] [Abstract][Full Text] [Related]  

  • 52. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer.
    Baekelandt MM; Holm R; Nesland JM; Tropé CG; Kristensen GB
    Anticancer Res; 2000; 20(2B):1061-7. PubMed ID: 10810398
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
    Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Intraperitoneal chemotherapy for ovarian cancer].
    Noma J; Yoshida N
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):885-90. PubMed ID: 18633214
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Chemotherapy of advanced ovarian carcinoma. I. First-choice treatment].
    Angelini F; Carassai A; Lopez M
    Clin Ter; 1988 Dec; 127(6):453-62. PubMed ID: 2977319
    [No Abstract]   [Full Text] [Related]  

  • 56. The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer.
    Huober J; Meyer A; Wagner U; Wallwiener D
    J Cancer Res Clin Oncol; 2002 Mar; 128(3):153-60. PubMed ID: 11935302
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intraperitoneal cisplatin chemotherapy in ovarian carcinoma patients who are clinically in complete remission.
    Menczer J; Ben-Baruch G; Rizel S; Brenner H
    Gynecol Oncol; 1992 Aug; 46(2):222-5. PubMed ID: 1500025
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Effectiveness of 3-drug therapy in patients with advanced ovarian cancer].
    Kwaśniewska-Rokicińska C; Kaleta B; Kumor-Głodny T
    Ginekol Pol; 1989 Feb; 60(2):86-9. PubMed ID: 2680790
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Controversies regarding intraperitoneal chemotherapy for advanced ovarian cancer].
    Miron L; Onofriescu M; Marinca M
    Rev Med Chir Soc Med Nat Iasi; 2008; 112(3):583-9. PubMed ID: 20201236
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
    du Bois A; Lück HJ; Meerpohl HG
    Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.